checkAd

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Company’s work in Dravet syndrome have been accepted for presentation at the American Epilepsy Society (AES) 2022 Annual Meeting, taking place December 2 – 6, in Nashville, Tennessee. The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.

“Topline results from a recent interim analysis showed marked reductions in seizure frequency, which support our work to develop STK-001 as potentially the first disease modifying medicine for Dravet syndrome,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. “We look forward to sharing more details from this interim analysis, along with several other presentations with researchers, clinicians and the Dravet syndrome community at the upcoming AES meeting.”

Details for the Company’s poster presentations at AES are as follows:

The same data from a combined analysis of MONARCH and ADMIRAL will be presented in two posters.

  • Title: ADMIRAL: A Phase 1/2a UK Study Investigating the Safety and Pharmacokinetics (PK) of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS)
    Session Date & Time: Saturday, December 3 at 12:00 PM CST
    Presenter: Helen Cross, MB ChB, Ph.D., Professor, The Prince of Wales’s Chair of Childhood Epilepsy and Head of the Developmental Neuroscience Programme at University College London Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology, President of the International League Against Epilepsy
    Poster Number: 1.215

  • Title: MONARCH Interim Analyses: A Phase 1/2a U.S. Study Investigating Safety and Drug Exposure of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS)
    Session Date & Time: Saturday, December 3 at 12:00 PM CST
    Presenter: Linda Laux​, M.D., Associate Professor of Pediatrics (Neurology and Epilepsy) at Northwestern University Feinberg School of Medicine and Attending Physician at Ann & Robert H. Lurie Children's Hospital of Chicago
    Poster Number: 1.227

Five additional posters from the Company’s Dravet syndrome program will be presented.

  • Title: SWALLOWTAIL: An Open-Label Extension (OLE) Study for Children and Adolescents with Dravet Syndrome (DS) who Previously Participated in a Study of Antisense Oligonucleotide (ASO) STK-001
    Seite 1 von 5




0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  119   |   |   

Schreibe Deinen Kommentar

Disclaimer

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the …

Nachrichten des Autors

352 Leser
116 Leser
108 Leser
108 Leser
108 Leser
108 Leser
108 Leser
108 Leser
104 Leser
100 Leser
824 Leser
668 Leser
616 Leser
588 Leser
460 Leser
416 Leser
396 Leser
396 Leser
380 Leser
368 Leser
3236 Leser
2100 Leser
1772 Leser
1604 Leser
1512 Leser
1180 Leser
1176 Leser
1140 Leser
1032 Leser
1020 Leser
7528 Leser
3236 Leser
3081 Leser
2934 Leser
2497 Leser
2460 Leser
2370 Leser
2169 Leser
2106 Leser
2100 Leser